Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives $39.50 Average Target Price from Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have received a consensus recommendation of “Moderate Buy” from the thirteen analysts that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $39.50.

A number of analysts recently commented on GMAB shares. New Street Research set a $43.00 price target on Genmab A/S in a report on Wednesday, July 22nd. Guggenheim upped their price objective on shares of Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 7th. Truist Financial started coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price on the stock. Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. Finally, TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and raised their price target for the stock from $32.00 to $43.00 in a report on Wednesday, July 22nd.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $33.53 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The firm has a 50-day moving average of $30.74 and a 200-day moving average of $28.19. Genmab A/S has a one year low of $23.62 and a one year high of $35.43. The company has a market cap of $20.92 billion, a P/E ratio of 26.40, a P/E/G ratio of 1.99 and a beta of 0.84.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Equities research analysts forecast that Genmab A/S will post 1.17 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

A number of institutional investors have recently added to or reduced their stakes in GMAB. CIBC Private Wealth Group LLC increased its position in shares of Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after buying an additional 616 shares during the period. Osaic Holdings Inc. lifted its holdings in shares of Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares in the last quarter. V Square Quantitative Management LLC bought a new position in shares of Genmab A/S in the first quarter valued at approximately $34,000. NewEdge Advisors LLC boosted its position in shares of Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares during the period. Finally, Brown Brothers Harriman & Co. grew its stake in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.